What is Castle Biosciences's market cap?

Castle Biosciences (CSTL) has a market capitalization of $1.1B and trades on NASDAQ.

What is Castle Biosciences's revenue and profitability?

Castle Biosciences generated $357.3M in trailing twelve-month revenue with a net loss of $19.4M, representing a net margin of -5.4%. Gross margin stands at 77.3%. The latest reported period is Q2 2026.

Who are Castle Biosciences's competitors?

Castle Biosciences's key competitors include Veracyte, Lucid Diagnostics, Myriad Genetics Inc, and others. These companies compete in similar markets and product categories.

Who does Castle Biosciences partner with?

Castle Biosciences's notable partners include SciBase Holding AB, The Washington University, ThermoFisher Scientific, Inc., and others.

What subsidiaries does Castle Biosciences have?

Castle Biosciences's subsidiaries include Previse, AltheaDx, Inc., Cernostics, Inc..

Where is Castle Biosciences headquartered?

Castle Biosciences is headquartered in United States of America and employs approximately 638 people. It has been publicly traded since 2019.

Castle Biosciences (CSTL) Stock Fundamentals & Financials

Castle Biosciences is a molecular diagnostics company that develops and commercializes innovative testing solutions for dermatologic cancers, gastroenterology, and ophthalmology.

Market cap

$1.14B+15.9%

Revenue$357.3M+3.2%

Net income-$19.4M-105%

EPS (diluted)-$0.65-85.7%

Trailing twelve months · change vs. prior year

Earnings

Q2 2026 report

July 30, 2026

Revenue$103.5MBeat by $17.3M EPS-$0.07Beat by $0.34

Read the full report

Next report

Nov 5, 2026 (In 2 days)

Revenue estimate$92.8M

EPS estimate-$0.35

Financials

Q2 2026

Income statement

See full

Revenue$103.5M+20.1%

Gross profit$79.8M+16.5%

Operating income-$3.1M+27.8%

Net income-$2.1M-146%

EPS (diluted)-$0.07-147%

Balance sheet

See full

Cash & equivalents$62.1M-24.5%

Total debt$36.7M-1.9%

Total equity$470.0M+3.2%

Total assets$561.2M+3.0%

Cash flow

See full

CapEx$8.7M-6.6%

Valuation & ratios

Valuation

See full

Market cap$1.14B+15.9%

Enterprise value$1.11B+57.3%

P/S3.2×+1.0×

Profitability

See full

Gross margin77.3%-3.7pp

Operating margin-9%+4.8pp

Net margin-5.4%+441pp

Returns & leverage

See full

Return on equity-4.2%+77.6pp

Debt / equity0.1×0.0×

Current ratio6×-0.8×

Segments

By product

See full

Non-Dermatologic$54.8M+83.5%

Dermatologic$48.7M-13.5%

By segment

See full

Reportable Segment$103.5M+20.1%

Competitors

By market cap

Labcorp Holdings$29.3B+39.2%

Veracyte$4.0B+41.6%

GeneDx Holdings$2.1B-48.0%

Personalis, Inc.$1.7B+97.6%

Castle Biosciences$1.1B+53.5%

Myriad Genetics$607.4M-18.8%

Lucid Diagnostics$77.3M-51.1%

ONC

Onconetix, Inc.$3.3M-37.4%

By revenue growth

GeneDx Holdings+25.4%

Lucid Diagnostics+24.9%

Veracyte+17.3%

Labcorp Holdings+6.0%

Castle Biosciences+3.2%

Myriad Genetics-3.2%

Personalis, Inc.-13.3%

By net margin

Veracyte20.37%+14.9pp

Labcorp Holdings6.88%+0.7pp

Castle Biosciences-5.43%-2.7pp

Myriad Genetics-13.96%+33.5pp

GeneDx Holdings-23.4%—

Personalis, Inc.-153.84%-40.1pp

Lucid Diagnostics-959.76%+308pp

Profile

Castle Biosciences is a molecular diagnostics company that develops and commercializes innovative testing solutions for dermatologic cancers, gastroenterology, and ophthalmology. The company leverages multi-analyte assays with algorithmic analysis and machine learning to provide personalized genomic information that aids clinicians in diagnosis, risk stratification, and treatment selection.

Competitive position

A leading provider of proprietary gene expression profile tests for skin cancer with a significant established market presence in uveal melanoma and expanding footprint in gastroenterology.

GeographiesUnited States

Customer segmentsSpecialist Physicians, Medical Laboratories, Health Insurance Payors

Business modelDiagnostic Testing Services, Direct Sales, Intellectual Property Licensing

SuppliersSole-source reagent suppliers, Laboratory equipment manufacturers, Academic research institutions for IP licensing

CustomersMedicare and government payors, Commercial health insurance companies, Specialty physician clinics, Hospitals

CountryUnited States of America

Listed2019

Employees638.0

CEODerek J. Maetzold

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websitecastlebiosciences.com

FilingsSEC EDGAR

FAQ

What is Castle Biosciences's market cap?: Castle Biosciences (CSTL) has a market capitalization of $1.1B and trades on NASDAQ.
What is Castle Biosciences's revenue and profitability?: Castle Biosciences generated $357.3M in trailing twelve-month revenue with a net loss of $19.4M, representing a net margin of -5.4%. Gross margin stands at 77.3%. The latest reported period is Q2 2026.
Who are Castle Biosciences's competitors?: Castle Biosciences's key competitors include Veracyte, Lucid Diagnostics, Myriad Genetics Inc, and others. These companies compete in similar markets and product categories.
Who does Castle Biosciences partner with?: Castle Biosciences's notable partners include SciBase Holding AB, The Washington University, ThermoFisher Scientific, Inc., and others.
What subsidiaries does Castle Biosciences have?: Castle Biosciences's subsidiaries include Previse, AltheaDx, Inc., Cernostics, Inc..
Where is Castle Biosciences headquartered?: Castle Biosciences is headquartered in United States of America and employs approximately 638 people. It has been publicly traded since 2019.

Ask your AI about Castle Biosciences.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude